Full Press Release Details
IDEAYA and Amgen Achieve First Patient In for Clinical Evaluation of IDE397 MAT2A and AMG 193 PRMT5 MTA Combination in MTAP Tumors.
IDYA
IDEAYA and Amgen Achieve First Patient In for Clinical Evaluation of IDE397 MAT2A and AMG 193 PRMT5 MTA Combination in MTAP Tumors
Key Takeaway: IDEAYA and Amgen Achieve First Patient In for Clinical Evaluation of IDE397 MAT2A and AMG 193 PRMT5 MTA Combination in MTAP Tumors
Price reaction · baseline $22.41 (2023-08-01 close) · hit after-hours · clean, no other IDYA news in the window
day 0 close · peak
-2.4%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma